Compare SUNS & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | OVID |
|---|---|---|
| Founded | 2023 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 365.5M |
| IPO Year | N/A | 2017 |
| Metric | SUNS | OVID |
|---|---|---|
| Price | $7.63 | $2.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $8.75 | $4.20 |
| AVG Volume (30 Days) | 107.9K | ★ 3.5M |
| Earning Date | 03-12-2026 | 03-18-2026 |
| Dividend Yield | ★ 15.09% | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | $91.00 | N/A |
| Revenue Next Year | $20.79 | N/A |
| P/E Ratio | $8.84 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $7.77 | $0.24 |
| 52 Week High | $11.78 | $2.72 |
| Indicator | SUNS | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 23.44 | 53.32 |
| Support Level | N/A | $1.31 |
| Resistance Level | $10.27 | $2.38 |
| Average True Range (ATR) | 0.29 | 0.20 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 13.77 | 31.74 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.